DSM says plans to cut 1, 100 jobs prompted by recent pharma moves not shareholder

Posted On Jul 23 2017 by

#dsm pharma # DSM says plans to cut 1,100 jobs prompted by recent pharma moves not shareholder pressure By Gareth MacDonald+ Gareth MACDONALD 25-Aug-2015 2015-08-25T00:00:00Z Last updated on 26-Aug-2015 at 13:46 GMT 2015-08-26T13:46:47Z Royal DSM will make up to 1100 staff redundant by the end of 2017 to cut costs following the formation of its Sinochem JV and pharma products deal with Patheon. The Dutch supplier announced the job cuts today, explaining that the move will save it €125m to €150m ($144m to $173m) over the next two years. DSM said around half of the job cuts will be at …


Aurobindo gets ready to play with the big boys #pharmaceutical #manufacturer

Posted On Jul 23 2017 by

#aurobindo pharma # Aurobindo gets ready to play with the big boys B Dasarath Reddy | Hyderabad Jul 25, 2016 12:39 AM IST Hyderabad-based Aurobindo Pharmaceuticals is planning to raise funds via a share sale to fund the acquisition of Israel-based Teva Pharmaceutical s European assets, if its bid is accepted by this month. The company is in a race with two other multinationals for the acquisition. Good profits and a near-doubling of its market value has given the company a confidence booster for the acquisition. Which could cost it as much as $1.3 billion (Rs 8,700 crore). For the …


Patheon and DSM complete $ merger to form private company DPx #new #pharmaceutical #companies #2013

Posted On Jul 23 2017 by

#dsm pharma # Patheon and DSM complete $2.65bn merger to form private company ‘DPx’ By Dan Stanton+ Dan Stanton 12-Mar-2014 2014-03-12T00:00:00Z Last updated on 12-Mar-2014 at 09:49 GMT 2014-03-12T09:49:12Z Patheon has merged with Royal DSM’s pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world’s second biggest CMO. Plans for the merger were announced in November last year, but the deal only completed yesterday. Under the new structure Patheon’s owner JLL Holdings has a 51% share in DPx with Royal DSM who controlling the remaining 49%. The new company will consist of …


Forest Laboratories to Acquire Furiex Pharmaceuticals #kemwell #pharma

Posted On Jul 23 2017 by

#forrest pharma # Forest Laboratories to Acquire Furiex Pharmaceuticals Today, Forest Laboratories Inc. announced that it has entered into a definitive agreement to acquire Furiex Pharmaceuticals, Inc. for up to $1.5 billion. Under the deal, Forest Laboratories will pay $95 per share, or approximately $1.1 billion in cash, and up to $30 a share, or $360 million, in contingent value rights tied to Furiex’s lead product candidate eluxadoline for irritable bowel syndrome (IBS). Forest Laboratories also announced that it has reached an agreement to sell Furiex’s royalties on alogliptin and Priligy with Royalty Pharma AG for approximately $415 million upon …


Teva to buy Barr Pharma for more than $7b #list #of #pharma #companies

Posted On Jul 22 2017 by

#barr pharma #from the September 2008 issue Teva to buy Barr Pharma for more than $7b. Teva Pharmaceutical confirmed its purchase of rival generic drugmaker Barr Pharmaceuticals for nearly $7.5 billion in a move that will boost Teva’s dominance as the world’s largest generic drugmaker. The deal continues consolidation of the generic-drug sector, driven by growth prospects as governments and other payers turn to the lower-priced medications and by the impending expiration of brand-name drug patents worth billions of dollars a year. Israel-based Teva Pharmaceutical Industries Ltd. said acquiring Montvale, N.J.-based Barr Pharmaceuticals Inc. the world’s No. 4 generic drug …


Sun Pharma to acquire US dermatology company DUSA Pharma #pharma #manufacturer

Posted On Jul 22 2017 by

#dusa pharma # Sun Pharma to acquire US dermatology company DUSA Pharma (Under the terms of the agreement, ) AHMEDABAD: Mumbai-based Sun Pharmaceutical Industries Ltd is set to acquire US-based DUSA Pharmaceuticals, Inc, a dermatology company focused on developing and marketing its Levulan (aminolevulinic acid HCl) photodynamic therapy platform. The two companies entered into a definitive agreement. Under the terms of the agreement, a 100% subsidiary of Sun Pharmaceutical Industries Ltd will commence a tender offer for all of the outstanding common stock of DUSA at a price of $8.00 per share in cash, a 38% premium to the closing …


Sun Pharma to buy Dusa for $230 million #largest #pharmaceutical #companies

Posted On Jul 22 2017 by

#dusa pharma # Sun Pharma to buy Dusa for $230 million Updated: Thu, Nov 08 2012. 11 43 PM IST Mumbai: Sun Pharmaceuticals Industries Ltd. India s most valuable drug maker, has agreed to buy US-based skincare speciality company DUSA Pharmaceuticals Inc. for $230 million ( Rs. 1,251 crore). Under the terms of the agreement, a subsidiary of Sun Pharma will commence a tender offer for all outstanding common stock of DUSA at a price of $8 per share in cash, a 38% premium to the closing price on 7 November, the Indian company said on Thursday. The transaction has …


Isis Pharma Changes – Unfortunate – Name to Avoid Confusion – Scientific American #pharma #sales

Posted On Jul 22 2017 by

#isis pharma # Isis Pharma Changes “Unfortunate” Name to Avoid Confusion The drugmaker – named after the Egyptian protector and healer goddess Isis, who was revered as a protector and healer – has been around for more than a quarter century. Credit: ManuelVelasco via iStock By Reuters Staff (Reuters) – After deliberating for most of the year, Isis Pharmaceuticals Inc said on Friday it would change its name to avoid being confused with the Islamist militant group known as ISIS. The biotechnology company said it would be called Ionis Pharmaceuticals Inc from Dec. 22 and also changed its stock exchange …


Amgen to Buy Onyx for $10 #valeant #pharma

Posted On Jul 22 2017 by

#onyx pharma # Amgen to Buy Onyx for $10.4 Billion to Gain Cancer Drug Amgen Inc. agreed to buy Onyx Pharmaceuticals Inc. in a $10.4 billion transaction that gives Amgen access to a rapidly expanding cancer-drug market with a new product that offers sure revenue. Amgen will pay $125 a share for Onyx’s outstanding stock, the companies said in a statement yesterday. Net of estimated Onyx cash, the deal is worth $9.7 billion. Onyx’s Kyprolis, approved last year for a rare blood cancer, may spur more than $3 billion in revenue by 2021, according to analyst estimates compiled by Bloomberg. …


Welcome to Elite Pharma Pvt #pharma #business

Posted On Jul 22 2017 by

#elite pharma # Welcome to Elite Pharma PVT. LTD. Elite Pharma Pvt. Ltd. a WHO-GMP certified company Elite Pharma Pvt. Ltd. is a well-reputed Pharma Manufacturing House always on a move for rapid progress & fast growth. We have our own Manufacturing Plant is located at Vatva, Ahmedabad in the State of Gujarat, which is the home of major Pharma units. The Company is promoted by a group of entrepreneurs with considerable experience in purchasing, manufacturing and marketing of formulations, viz. General Category Tablets, Capsules and Oral Liquids as well as Beta-Lactum Category Tablets, Capsule & Dry Powder. The main …